Stay updated on Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page
- Check6 days agoChange DetectedFooter revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded 'Gastric cancer' as a topic label and included a 'Genetic and Rare Diseases Information Center' resource in the Resources section. This supplements patient information without modifying trial details.SummaryDifference0.2%

- Check34 days agoChange DetectedThe page now shows a new revision tag: Revision: v3.4.2. The older notice about lapse in government funding and operating status has been removed.SummaryDifference0.5%

- Check41 days agoChange DetectedThe update consists of an administrative notice about government funding and a revision tag from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check48 days agoChange DetectedThe update primarily adds UI elements and expands glossary/metadata labels (Show glossary, IPD data planning terms, and related MeSH terms) across the page, with no changes to the core study details, eligibility criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference48%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This is a minor version update with no visible changes to the study content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.